home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

270 rows where filing_period = "fourth_quarter", filing_year = 2017 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 270 ✖

filing_year 1

  • 2017 · 270 ✖

filing_period 1

  • fourth_quarter · 270 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2057445 RED+BLUE STRATEGIES dfe1d04b-09c5-4256-aa9b-5e9bdced1e35 Q4 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2017 fourth_quarter PHA Work to reconsider current CMS position on the structure of the Medicare J-Code for biosimilar medications. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-01-02T10:09:20.523000-05:00
2057954 AMERICAN COLLEGE OF CLINICAL PHARMACY e6e984b7-e81c-4a6d-a595-630f36b63ad5 Q4 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2017 fourth_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   128375 0 0 2018-01-04T09:46:44.613000-05:00
2058245 AMERICAN PHARMACISTS ASSOCIATION 643b61ab-6146-41a2-ba4a-da13cb0ea3a6 Q4 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2017 fourth_quarter PHA HR 1038, S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act HR 1939 To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes. HR 592, S 109 To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services. HR 1480 Safe and Affordable Drugs from Canada Act of 2017 S 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 HR 1586 To amend the Federal Food, Drug, and Cosmetic Act to ensure that liquid over-the-counter medications are packaged with appropriate dosage delivery devices and, in the case of such medications labeled for pediatric use, appropriate flow restrictors, and for other purposes. S 778 Prescription Drug Monitoring Act of 2017 HR 934 Personal Drug Importation Fairness Act of 2017 HR 421 Allowing Greater Access to Safe and Effective Contraception Act HR 1436 To provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017. HR 1245, S 469 To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals. HR 3268 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018 (drug compounding provisions) S 1079 Protecting Americans from Dangerous Opioids Act HR 2567 Access to Birth Control Act HR 2871 Preserving Patient Access to Compounded Medications Act of 2017 HR 2063 Opioid PACE Act of 2017 S 1003 A bill to amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes HR 1939/S 1044 Ensuring Seniors Access to Local Pharmacies Act of 2017 S 469 Affordable and Safe Prescription Drug Importation Act HR 3727 To amend title XVIII of t… HOUSE OF REPRESENTATIVES,SENATE   34000 0 0 2018-01-05T14:21:42.550000-05:00
2058767 AMERICAN CAPITOL GROUP c08eb5f7-acb0-46d7-a5a5-be285380f66c Q4 AMERICAN CAPITOL GROUP 305852 CARDINAL HEALTH 2017 fourth_quarter PHA Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services; Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2018-01-09T09:31:48.527000-05:00
2059350 PARRY, ROMANI, DECONCINI & SYMMS 57af036b-c922-40a8-94fd-56073f4778e6 Q4 PARRY, ROMANI, DECONCINI & SYMMS 30792 ROCK & ASSOCIATES 2017 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 12000   0 0 2018-01-10T11:49:54.897000-05:00
2059687 LUNGREN LOPINA LLC 4eccb1d8-dafd-4c7d-9e50-f07218465364 Q4 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2017 fourth_quarter PHA Fair treatment for US pharmaceutical ingredients   40000   0 0 2018-01-10T15:34:09.853000-05:00
2059821 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 77959816-d900-4c89-9142-06065f112062 Q4 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 24486 INOVIO PHARMACEUTICALS 2017 fourth_quarter PHA Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-01-10T16:52:50.220000-05:00
2059916 ACG ADVOCACY 0876944e-5682-4d4a-9759-46ac67c10a63 Q4 ACG ADVOCACY 2057 WALGREEN CO. 2017 fourth_quarter PHA Competition Policy Issues. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-01-10T19:00:24.260000-05:00
2059965 MR. BRIAN KELLY 48c94aa8-ea55-4dde-88f2-e3069310e3b6 4T MR. BRIAN KELLY 40024191 LUNDBECK PHARMACEUTICALS 2017 fourth_quarter PHA CNS Brain Disorders Alzheimer's HOUSE OF REPRESENTATIVES,SENATE 15000   0 1 2018-01-11T09:46:36.007000-05:00
2060061 BALLARD PARTNERS 3e537baf-fbed-4669-a051-9067bd95dce0 Q4 BALLARD PARTNERS 401104288 LABORATORY CORPORATIONS OF AMERICA HOLDINGS 2017 fourth_quarter PHA The registrant will advise and advocate for the client on general government policies and regulations. Health & Human Services, Dept of (HHS),White House Office 60000   0 0 2018-01-11T10:51:51.517000-05:00
2060217 KATE MOSS 129c5579-cfa1-4056-b9a4-3735e5a4c83d Q4 KATE MOSS 25988 CVS HEALTH 2017 fourth_quarter PHA Legislation impacting PBMs and drug pricing HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-01-11T12:03:32.473000-05:00
2060281 FARRAGUT PARTNERS LLP 1c3a123d-a112-4539-a8f3-0c20e304eeff Q4 FARRAGUT PARTNERS LLP 401103938 AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS 2017 fourth_quarter PHA Issues pertaining to Prescription Drug Monitoring programs. Public Health. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-01-11T13:23:52.323000-05:00
2060303 FARRAGUT PARTNERS LLP 9e271216-a5c0-4f40-96ad-c85e4a8b5d35 Q4 FARRAGUT PARTNERS LLP 401103938 GENENTECH 2017 fourth_quarter PHA Prescription Drug User Fee Act reathorization. Oversight of 340B drug discount program. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-01-11T13:35:12.157000-05:00
2060315 FARRAGUT PARTNERS LLP 74fdc2d0-cdfd-4cc2-93cf-9d2677a40fc7 Q4 FARRAGUT PARTNERS LLP 401103938 BLUE CROSS BLUE SHIELD ASSOCIATION 2017 fourth_quarter PHA Laboratory developed tests 21st Century Cures HR 6 21st Century Cures Act Introduced May 19, 2015 by Fred Upton (RMI) This bill amends the Public Health Service Act to reauthorize the National Institutes of Health (NIH) through FY2018. The NIH Innovation Fund is established to fund a strategic plan, early stage investigators, and highrisk, highreward research. The NIH may require scientific data to be shared if the research is fully funded by the NIH. The NIH and the Food and Drug Administration (FDA) must implement a system that allows further research on clinical trial data. The Centers for Disease Control and Prevention must expand surveillance of neurological diseases. The Council for 21st Century Cures is established to accelerate the discovery, development, and delivery of innovative cures, treatments, and preventive measures. The Department of Health and Human Services must monitor the use of antibacterial and antifungal drugs and resistance to these drugs Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,Treasury, Dept of,White House Office 50000   0 0 2018-01-11T13:45:24.867000-05:00
2060321 FARRAGUT PARTNERS LLP 8add122c-e8d0-4199-907e-0f10724abf43 Q4 FARRAGUT PARTNERS LLP 401103938 COMMUNITY ONCOLOGY ALLIANCE 2017 fourth_quarter PHA Issues related to pharmacy benefit managers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-01-11T13:45:30.523000-05:00
2060345 FARRAGUT PARTNERS LLP fb5d627b-f40d-4beb-bd86-be0eabde3c34 Q4 FARRAGUT PARTNERS LLP 401103938 HERON THERAPEUTICS, INC. 2017 fourth_quarter PHA Issues related to opioids and FDA issues. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-01-11T13:50:45.587000-05:00
2060561 WAXMAN STRATEGIES 7b5f62df-c48e-404f-875d-4251774889cc Q4 WAXMAN STRATEGIES 401103693 340B HEALTH 2017 fourth_quarter PHA Issues affecting the 340B drug pricing program HOUSE OF REPRESENTATIVES,SENATE 18750   0 0 2018-01-11T15:41:03.830000-05:00
2060804 NCHC ACTION FUND cb211d5e-2f50-420f-bfe4-60dadeea34cb Q4 NCHC ACTION FUND 401104187 NCHC ACTION FUND 2017 fourth_quarter PHA Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   10000 0 0 2018-01-11T20:05:33.167000-05:00
2060843 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER a3f58e52-aa52-4d94-8b75-ad32dd64b340 Q4 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2017 fourth_quarter PHA 340B drug pricing, PREA Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   61052 0 0 2018-01-12T09:04:53.273000-05:00
2061009 AMERICAN COLLEGE OF CLINICAL PHARMACY 10fb36d7-589d-4a1b-b142-b9a98fc34f71 4A AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2017 fourth_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   128375 0 0 2018-01-12T10:02:24.520000-05:00
2061223 MCDERMOTT+ LLC 63f3cebd-3da5-4d78-b7b7-5fb5c148ccfa Q4 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2017 fourth_quarter PHA Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-01-12T13:27:46.607000-05:00
2061533 ACADEMY OF MANAGED CARE PHARMACY dfc252b9-29eb-480b-8366-8d7631331dc2 Q4 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2017 fourth_quarter PHA Joint letter with other pharmacy associations submitted for the record in the House Energy and Commerce committee hearing on opioids in support of pharmacists being eligible for DATA waivers to provide Medication Assisted Therapy, Comments submitted to HHS Notice of Benefit and payment parameters for 2019;Comments submitted to FDA on direct to consumer advertising, Comments submitted to FDA on potential areas of focus for the opioid policy steering committee, comments submitted to the FTC on solutions and strategies to improve generic competition in the marketplace, comments submitted in response to a request for information from the House of Representatives Diabetes Caucus for information on value based contracting, dissemination of pharmaeconomic information, and H.R. 2026 Pharmaceutical Information Exchange Act. Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES   82000 0 0 2018-01-12T17:45:30.883000-05:00
2061537 INDEPENDENT PHARMACY COOPERATIVE 8e8a44be-4ab5-42cc-a448-13e00e2df559 Q4 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2017 fourth_quarter PHA Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act Support S.413/H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision. Support S. 413 / H.R. 1038 the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act" Support H.R. 2871 the "Preserving Patient Access to Compounded Medications Act of 2017 Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2018-01-12T17:50:33.730000-05:00
2061583 THE D MAJOR GROUP 8530e0df-863d-43aa-8875-2cd625253132 Q4 THE D MAJOR GROUP 401103162 ALLERGAN INC (FORMERLY ACTAVIS INC ) 2017 fourth_quarter PHA Monitor issues concerning bioequivalence standards for pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 48000   0 0 2018-01-12T21:30:07.730000-05:00
2061602 THE D MAJOR GROUP c4078e3d-af4f-49a0-8ed2-87bdaf9ded43 4T THE D MAJOR GROUP 401103162 CVS CAREMARK 2017 fourth_quarter PHA Advocate for the protection of PBM business methods and corresponding health savings. HOUSE OF REPRESENTATIVES,SENATE 30000   0 1 2018-01-12T23:12:24.893000-05:00
2061611 RED+BLUE STRATEGIES 4e55940e-4b46-4dd9-904a-ff6a38349c96 Q4 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2017 fourth_quarter PHA CMS regulations regarding the Part D program and the role of prescription drug plans. S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 281- National Defense Authorization Act for FY 2018- Issues related to prescription medications for military personnel and their families. H.R. 3447 - Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 - Working to explain the need for safe and confidential data sharing between Medicare part A, B, and D to ensure better coordination of patient care. Issues related to Direct and Indirect Renumeration policies and their impact on consumers. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-01-13T10:09:39.513000-05:00
2061675 AMERICAN AMBULANCE ASSOCIATION 88635bdf-9101-4c7b-8189-4367b085be76 Q4 AMERICAN AMBULANCE ASSOCIATION 56018 AMERICAN AMBULANCE ASSOCIATION 2017 fourth_quarter PHA Lobbied for passage of Protecting Patient Access to Emergency Medication Act (H.R. 304, S. 916). Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   280000 0 0 2018-01-13T13:35:11.637000-05:00
2061707 CHATMAN, LLC 4155b9cd-1809-467b-87be-0edeea7b8262 Q4 CHATMAN, LLC 400678024 LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER 2017 fourth_quarter PHA Support continuation of Pharmacy 340B program in HRSA. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-01-13T19:12:51.403000-05:00
2061771 RED+BLUE STRATEGIES ee285ca0-8c9c-491a-a067-99001e19ac42 Q4 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2017 fourth_quarter PHA CMS Regulations related to the Medicare Part D program and Prescription Drug Plans (PDPs) S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D. Issues related to lowering the price of prescription medications in the United States. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-01-14T18:21:08.607000-05:00
2061774 RED+BLUE STRATEGIES 00ad7851-d810-40d9-9f13-7e7022028938 Q4 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2017 fourth_quarter PHA CMS regulations related to Medicare Part D and promulgation of laws related to curbing substance use disorder among Medicare beneficiaries. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement. Issues related opioid abuse and methods to fight against the opioid epidemic in the United States. Issues related to ensuring the safety of compounded medications. Issues related to over the counter medications and supplements. Issues related to the Physician Payment Sunshine Act and the Open Payments system. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-01-14T18:30:10.057000-05:00
2061811 RED+BLUE STRATEGIES ea6c79b3-76de-413f-b05d-e3a2515155f2 Q4 RED+BLUE STRATEGIES 400693064 BLUE CROSS BLUE SHIELD OF MASSACHUSETTS 2017 fourth_quarter PHA Issues related to curbing the abuse of opioids in the United States. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-01-15T10:26:06.407000-05:00
2061866 ISEMAN & ASSOCIATES LLC b5bfd22f-6870-4ddb-8c04-a499408bf553 Q4 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2017 fourth_quarter PHA Monitoring biotech legislation HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-01-15T10:52:29.570000-05:00
2062510 ELI LILLY AND COMPANY 10d2768f-3305-4929-8b09-eebcf9edd7dc Q4 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2017 fourth_quarter PHA Hospital discounts; 340B program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1560000 0 0 2018-01-16T09:09:28.307000-05:00
2062952 MCDERMOTT WILL & SCHULTE LLP d106c9d3-1c50-40bd-b053-2bb083b9fee3 Q4 MCDERMOTT WILL & SCHULTE LLP 24338 MAXOR NATIONAL PHARMACY SERVICES, LLC 2017 fourth_quarter PHA Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, the 340B Program. (Jeff Miller -- Executive Branch lobbying only, until 1/3/2018.) HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2018-01-16T12:13:10.880000-05:00
2063736 MERCY HEALTH SYSTEM dd461989-dbd1-40d0-a6fa-4291992d4258 Q4 MERCY HEALTH SYSTEM 40043344 MERCY HEALTH SYSTEM 2017 fourth_quarter PHA Palliative Care 340 B Drug program Health Care Reform HOUSE OF REPRESENTATIVES,SENATE     0 0 2018-01-16T16:35:27.543000-05:00
2063752 ELI LILLY AND COMPANY dff15bd4-c873-40b8-a8d8-fc98b109cac6 4A ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2017 fourth_quarter PHA Hospital discounts; 340B program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   2170000 0 0 2018-01-16T16:43:35.120000-05:00
2064865 ROCK & ASSOCIATES 3da5c862-1d91-4972-aa93-dcd17408332e Q4 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2017 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-01-17T12:23:12.120000-05:00
2064869 ROCK & ASSOCIATES 8adc2bcd-88dc-4069-8e5a-afce679a1a37 Q4 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2017 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-01-17T12:24:15.447000-05:00
2064873 ROCK & ASSOCIATES 2716a887-7c1c-40a3-a24b-8ac5ea06e59b Q4 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2017 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-01-17T12:25:16.590000-05:00
2064880 ROCK & ASSOCIATES 70fedf9c-ba4b-4751-814c-71ca767dd32f Q4 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2017 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-01-17T12:26:18.980000-05:00
2064887 ROCK & ASSOCIATES c9c6cbf3-3fa4-4cf3-aea9-349077b59ceb Q4 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2017 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-01-17T12:27:23.417000-05:00
2064888 ROCK & ASSOCIATES ee843bd2-45d7-431a-8f16-8ef422863d5c Q4 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2017 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-01-17T12:28:24.527000-05:00
2064899 ROCK & ASSOCIATES f694385d-0ee2-425d-8e9c-7f142f6b6f42 4A ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2017 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-01-17T12:30:29.370000-05:00
2064901 ROCK & ASSOCIATES f66bcc4c-7cbb-4e20-ae9a-55e84eb42fc2 Q4 ROCK & ASSOCIATES 33545 PRECISION PHARMACY 2017 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-01-17T12:31:30.837000-05:00
2065022 SQUIRE PATTON BOGGS 6a7f6940-3771-48d0-91fb-d6bc986717fe Q4 SQUIRE PATTON BOGGS 30906 BIOTECHNOLOGY INNOVATION ORGANIZATION 2017 fourth_quarter PHA Monitoring legislation that could impact pharmaceutical industry. Commerce, Dept of (DOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-01-17T13:21:44.253000-05:00
2065086 AMERICAN CONSERVATIVE UNION 74c5c464-e0e9-491f-83e3-86ef49f5941f Q4 AMERICAN CONSERVATIVE UNION 62712 AMERICAN CONSERVATIVE UNION 2017 fourth_quarter PHA S.974 - CREATES Act of 2017 H.R.2212 - CREATES Act of 2017 Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT),U.S. Trade Representative (USTR),White House Office   10000 0 0 2018-01-17T13:29:16.920000-05:00
2065245 WINNING STRATEGIES WASHINGTON e6fac8a1-5803-4262-b4c6-57db3aceb96b Q4 WINNING STRATEGIES WASHINGTON 50796 KALEO 2017 fourth_quarter PHA Pharmaceutical drug development including epinephrine for anaphylaxis Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE 30000   0 0 2018-01-17T14:00:34.160000-05:00
2065452 HOLLAND & KNIGHT LLP 4432a598-062e-4751-998e-e991e4326eab Q4 HOLLAND & KNIGHT LLP 18466 THE BIOSIMILARS FORUM 2017 fourth_quarter PHA Medicare reimbursement issues, FDA regulation of biosimilars; S. 934, H.R. 2430, the FDA Reauthorization Act of 2017. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2018-01-17T14:40:04.870000-05:00
2065508 HOLLAND & KNIGHT LLP cb915216-d37d-4dfb-a95d-f7cacda05d96 Q4 HOLLAND & KNIGHT LLP 18466 PROTECTING ACCESS TO PAIN RELIEF COALITION 2017 fourth_quarter PHA Advocating for policy to ensure patient access to pain relief; H.R. 664, Stop OD Act of 2017; S.1554, Safer Prescribing of Controlled Substances Act. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-01-17T14:54:46.460000-05:00
2065594 MERCURY PUBLIC AFFAIRS, LLC 8dfdd9bc-ec03-4215-b3ed-a424ec3ff1e0 Q4 MERCURY PUBLIC AFFAIRS, LLC 70175 MORRIS AND DICKSON 2017 fourth_quarter PHA IT Help RE Improper Prescriptions Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS) 20000   0 0 2018-01-17T15:11:47.080000-05:00
2066035 QUADRIPOINT STRATEGIES LLC edb1cba1-1171-40dd-ac5b-e1ad1f276e2e Q4 QUADRIPOINT STRATEGIES LLC 40002020 KALEO, INC 2017 fourth_quarter PHA opioid epidemic, naloxone availability Health & Human Services, Dept of (HHS),Office of the Vice President of the United States,White House Office 20000   0 0 2018-01-17T17:00:57.440000-05:00
2066120 SORINI, SAMET & ASSOCIATES, LLC a05461d7-94c0-46eb-aa8a-91fa53a3b7b5 Q4 SORINI, SAMET & ASSOCIATES, LLC 317754 PETSMART, INC. 2017 fourth_quarter PHA Veterinary prescriptions HOUSE OF REPRESENTATIVES,Intl Trade Administration (ITA),SENATE,U.S. International Trade Commission (ITC) 20000   0 0 2018-01-17T17:34:47.760000-05:00
2066160 KOUNTOUPES DENHAM CARR & REID, LLC 278f76c2-da8b-443d-89ec-fecff3e59833 Q4 KOUNTOUPES DENHAM CARR & REID, LLC 320918 GLENMARK PHARMACEUTICALS, INC., USA 2017 fourth_quarter PHA General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-01-17T17:51:11.193000-05:00
2066324 BROYDRICK & ASSOCIATES 1543845c-0f4c-444e-9ec0-cae1c591bb04 Q4 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2017 fourth_quarter PHA Funding for a new drug for PTSD. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-01-17T20:59:19.830000-05:00
2066622 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 34988295-d36f-4cc9-b8f5-77577b1279b9 Q4 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 400265214 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 2017 fourth_quarter PHA Pricing, shortages, and safety issues Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   176300 0 0 2018-01-18T08:42:46.307000-05:00
2066777 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) d6c0b808-e1b3-4f79-a4fa-c9554adc6e06 Q4 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2017 fourth_quarter PHA Ensuring Patient Access and Effective Enforcement Act (Public Law 114-145); Prescription Drug Abuse - General issues related to Rx drug abuse; Importation of Prescription Drugs (S 469, S 771, HR 1776, HR 1245, HR 934, HR 1480, S 92, S 64), Implementation of Public Law 113-54 (DSCSA) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   353232 0 0 2018-01-18T09:46:08.443000-05:00
2066855 ELI LILLY AND COMPANY c9ca1bd6-6a7c-478d-bcb5-6eb8cd72c5f5 4A ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2017 fourth_quarter PHA Hospital discounts; 340B program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   2170000 0 0 2018-01-18T09:59:45.270000-05:00
2067100 KOUNTOUPES DENHAM CARR & REID, LLC e462f6e4-0b8e-496a-967f-a7804441c3a4 Q4 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2017 fourth_quarter PHA Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 2212 and S.974, the CREATES Act of 2017, and H. R. 2051, the Fair Access for Safe and Timely Generics (FAST) Generics Act of 2017. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 60000   0 0 2018-01-18T10:53:55.693000-05:00
2067352 AKIN GUMP STRAUSS HAUER & FELD e6b5e1c6-b40d-4071-a889-ac994785335f Q4 AKIN GUMP STRAUSS HAUER & FELD 682 PHARMEDIUM SERVICES, LLC 2017 fourth_quarter PHA Drug Quality and Security Act, Pub. L. 113-54; FDA regulatory implementation of Section 503B of the Food, Drug and Cosmetic Act; FDA Pharmacy Compounding Advisory Committee; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2018-01-18T11:42:23.037000-05:00
2067645 KOUNTOUPES DENHAM CARR & REID, LLC c2c5299a-c39b-4e40-a4d8-56686061ce8a Q4 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2017 fourth_quarter PHA General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-01-18T12:54:50.190000-05:00
2067755 MASSACHUSETTS MEDICAL SOCIETY fc4c8674-ba4e-487f-a299-c4742f663f91 Q4 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2017 fourth_quarter PHA S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions. Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2018-01-18T13:28:07.167000-05:00
2067770 OREGON HEALTH & SCIENCE UNIVERSITY 0d03fdf2-7eae-4e56-99c7-952aa5b720d9 Q4 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2017 fourth_quarter PHA 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. HOUSE OF REPRESENTATIVES,SENATE   80000 0 0 2018-01-18T13:30:17.057000-05:00
2068006 ICE MILLER LLP 22a28975-c005-423d-a413-936df38fd766 Q4 ICE MILLER LLP 67854 ELI LILLLY AND COMPANY 2017 fourth_quarter PHA Issues related to pharmaceutical research and manufacturing Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE     0 0 2018-01-18T14:10:53.013000-05:00
2068046 340B HEALTH 50326065-8138-44b6-b508-12a50b476590 Q4 340B HEALTH 316434 340B HEALTH 2017 fourth_quarter PHA The 340B Drug Pricing Program, FY18 LHHS Appropriations, final 2018 Outpatient Prospective Payment System Rule, final rule and new proposed rule concerning 340B ceiling price calculations and manufacturer civil monetary penalties Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE   255010 0 0 2018-01-18T14:19:15.950000-05:00
2068076 MERCURY PUBLIC AFFAIRS, LLC 11bcbce8-e6e1-432f-a67e-8d913ee3ca23 Q4 MERCURY PUBLIC AFFAIRS, LLC 70175 KALISPELL REGIONAL HEALTHCARE 2017 fourth_quarter PHA Veteran pharmacy issues and polices Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2018-01-18T14:23:32.230000-05:00
2068136 NELSON MULLINS RILEY & SCARBOROUGH 097f443f-31ce-403d-95d7-ef9aba6f7b97 Q4 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2017 fourth_quarter PHA Issues related to the 340B Drug Pricing Program and biomedical research HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-01-18T14:32:08.337000-05:00
2068631 CORNERSTONE GOVERNMENT AFFAIRS, INC. 26140bc1-2d47-4c5e-8c43-78b6f99aa9a2 Q4 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 CHILDREN'S NATIONAL MEDICAL CENTER 2017 fourth_quarter PHA Representation on health-related issues including reimbursement, research, public-health & clinical care Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2018-01-18T15:46:16.693000-05:00
2068781 CARD & ASSOCIATES, LLC 7743b331-7f3c-416b-9133-144db1a90f91 Q4 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2017 fourth_quarter PHA Educate Members on pharmacy contracting with pharmacy benefit managers H.R. 1316 Prescription Drug Price Transparency Act S. 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 CMS-4182-P Technical Changes Defining Mail Order Pharmacy and Retail Pharmacy Comments Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-01-18T16:18:56.433000-05:00
2068980 PUBLIC CITIZEN 6b9a6189-6896-4c57-8389-fb9e41dcdb61 Q4 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2017 fourth_quarter PHA S 771/HR1776-Improving access to affordable prescription drugs act, S 2011/HR 4138-Medicare Price Negotiation Act of 2017, S 252-Medicare Drug Savings Act of 2017, S 1369/HR 2974-Stop Price Gouging Act, S 124-Preserve access to affordable generics act, HR 4117-Competitive DRUGS Act of 2017, S 974/HR 2212-CREATES act of 2017, HR 2051-FAST generics Act of 2017, S 495-Medicare Innovation Prize Fund Act, S 1131.HR 2439-FAIR Drug Pricing act, HR 4116-Transparent Drug Pricing Act of 2017, S 1509-Orphan Products extension accelerating cures and treatments, HR 1223-OPEN act, S 1390-Stronger Patriots Act of 2017, S 1827-KIDS Act of 2017, HR 1628-American Health care act of 2017, HR 3921-Healthy KIDS Act, HR 4116-Transparent drug pricing act of 2017, Bipartisan Health Care Stabilization Act of 2017, biologic market exclusivity, inter partes review, direct to consumer advertising, Over-the-counter Monograph Safety Innovation and Reform act of 2017, Azar HHS nomination, Agriculture, Dept of (USDA),Education, Dept of,Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,Office of Government Ethics (OGE),Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR),White House Office   70000 0 0 2018-01-18T16:48:57.820000-05:00
2069031 SIMS STRATEGIES, LLC 66ac3f90-1018-4021-b6ba-1a5dadf63a3e Q4 SIMS STRATEGIES, LLC 401104546 GLAXOSMITHKLINE, INC. 2017 fourth_quarter PHA Education and importance of various pharmaceutical industry issues. SENATE 40000   0 0 2018-01-18T17:00:32.537000-05:00
2069048 SIMS STRATEGIES, LLC 03565ffd-9d94-4c1b-8c63-09dca91fa05f Q4 SIMS STRATEGIES, LLC 401104546 AMAG PHARMACEUTICAL 2017 fourth_quarter PHA Education on products and issues related to women's health. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-01-18T17:05:43.597000-05:00
2069128 KOUNTOUPES DENHAM CARR & REID, LLC d7edd87d-42bf-4e35-9714-3143347d5fba Q4 KOUNTOUPES DENHAM CARR & REID, LLC 320918 TEVA PHARMACEUTICALS USA, INC. 2017 fourth_quarter PHA Proposals related to affordability and pricing of pharmaceuticals including H. R. 2212 and S.974 Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-01-18T17:19:39.547000-05:00
2069246 PRIME THERAPEUTICS cac71a4a-b278-481a-89b3-1eee731ea89a Q4 PRIME THERAPEUTICS 400339576 PRIME THERAPEUTICS 2017 fourth_quarter PHA S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R. 3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only). HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2018-01-18T17:48:46.303000-05:00
2069395 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING a0bcf17e-34f3-4ed5-84c5-e63824fe22e8 Q4 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2017 fourth_quarter PHA Compounding of radiopharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE   30000 0 0 2018-01-18T18:51:08.053000-05:00
2069456 NATIONAL NURSES UNITED 1633a474-ad99-4f35-a3d6-f0f2f00143a8 Q4 NATIONAL NURSES UNITED 40021153 NATIONAL NURSES UNITED 2017 fourth_quarter PHA Supported legislation to permit Medicare Part D to negotiate pharmaceutical prices HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2018-01-18T19:22:53.467000-05:00
2069514 ALLERGAN USA, INC. dd87d5e7-a5d5-4154-bbb6-b2235c5793f3 Q4 ALLERGAN USA, INC. 63837 ALLERGAN USA, INC. 2017 fourth_quarter PHA Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding and the Drug Quality and Security Act of 2013 Drug Importation/Counterfeit Drugs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Patent & Trademark Office (PTO),SENATE   480000 0 0 2018-01-18T20:10:14.827000-05:00
2069529 CONNECT 4 STRATEGIES, LLC a5edbd2c-455f-4626-9c41-29a311a469d8 Q4 CONNECT 4 STRATEGIES, LLC 401103720 OREXO US, INC. 2017 fourth_quarter PHA s916 Access to Emergency Medications Act SENATE 20000   0 0 2018-01-18T20:26:26.763000-05:00
2069566 NOVO NORDISK INC. 09631fcb-958e-4d90-b197-8c7d8a6e69e0 Q4 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2017 fourth_quarter PHA Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act; H.R. 4710, the 340B Protecting Access for the Underserved and Safety-Net Entities Act (340 PAUSE Act)and other issues related to 340B program Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE   290000 0 0 2018-01-18T21:09:00.640000-05:00
2070227 NELSON MULLINS RILEY & SCARBOROUGH 852d888b-59ce-4237-9692-b9d4f012e96f Q4 NELSON MULLINS RILEY & SCARBOROUGH 285871 CASCADE HEMOPHILIA CONSORTIUM 2017 fourth_quarter PHA Issues related to 340B Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-01-19T09:29:35.667000-05:00
2070298 AMERICAN VETERINARY MEDICAL ASSOCIATION a0c92150-d8fe-43cb-b832-fc0ad6144287 Q4 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2017 fourth_quarter PHA H.R. 623 Fairness to Pet Owners Act Animal Drug User Fee Act; Animal Generic Drug User Fee Act Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   160000 0 0 2018-01-19T09:39:06.867000-05:00
2070364 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH cf2625d8-8087-4576-869d-c6ddd21fa8fc Q4 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 401104060 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 2017 fourth_quarter PHA Strengthening the Orphan Drug Tax Credit provision within the final bill, or at the very least ensuring the Senates 27.5 percent credit remains intact Environmental Protection Agency (EPA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Treasury, Dept of   24400 0 0 2018-01-19T09:47:51.707000-05:00
2070421 AARP e20d3370-3da6-425c-b707-6e7684a9da4e Q4 AARP 1694 AARP 2017 fourth_quarter PHA Provided comments to CMS on value-based pricing arrangements for prescription drugs. S. 974/H.R. 2212, CREATES Act - Discussed support of bill. H.R. 2051, FAST Generics Act - Discussed support of bill. S.1131/H.R. 2439, FAIR Drug Pricing Act - Discussed support of bill. S. 124, Preserve Access to Affordable Generics Act - Discussed support of bill. Advocated for biosimilar drugs to be added to the Medicare Part D Coverage Gap Discount Program. Cody Miller PMI Act - Participated in meetings with the sponsoring office to discuss updates to the bill text and re-introduction in the 115th Congress. Submitted a letter outlining the reforms we support to lower prescription drugs costs to the House Energy and Commerce Committee and the Senate HELP Committee when they held hearings on the drug supply chain. Discussed possible ways to improve Medicare Part D. Discussed Rx Price Watch Reports and the impact of high drug costs. Discussed drug pricing reforms AARP supports, including secretarial negotiation, importation, reducing exclusivity for biologics, and ending pay-for-delay deals. H.R. 3354, Omnibus Appropriations Act, 2018, H.R. 1370, H.J.R. 123, Further Continuing Appropriations Act, 2018, H.J. Res. 99 (P.L. 115-30), H.R. 244, Consolidated Appropriations Act 2017 (P.L. 115-31) and (H.R. 3358 & S. 1771) Agriculture-Rural Development & Related Agencies bill for FY 2018 - Lobbied in support of increased funding for FDA drug processing funding and user fees. Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Equal Employment Opportunity Commission (EEOC),Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Natl Highway Traffic Safety Administration (NHTSA),Securities & Exchange Commission (SEC),SENATE,Veterans Affairs, Dept of (VA)   3020000 0 0 2018-01-19T09:53:31.067000-05:00
2070467 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION e2f0f82d-3494-4825-88f0-81a0eeebb888 Q4 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2017 fourth_quarter PHA Congressional Oversight of 340 B Program; Issues related to FDA implementation of The Drug Quality and Security Act related to the regulations of pharmacy compounding; Biosimilar naming; H.R. 421 Allowing Greater Access to Safe and Effective Contraception Act; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017; HR 749, Lower Drug Costs through Competition Act Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Natl Economic Council (NEC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Treasury, Dept of,White House Office   480000 0 0 2018-01-19T10:00:58.767000-05:00
2070987 HUSCH BLACKWELL, LLP a2245e17-923d-4d02-b07d-ef5bf13eb4d1 Q4 HUSCH BLACKWELL, LLP 6303 ARJ INFUSION SERVICES, INC. 2017 fourth_quarter PHA Issues related to home infusion therapy; S.1738 HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-01-19T10:47:21.297000-05:00
2071094 FTI GOVERNMENT AFFAIRS 03b22b7a-f486-4613-9729-15556e3854f5 Q4 FTI GOVERNMENT AFFAIRS 401054971 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2017 fourth_quarter PHA Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R.2871 "Preserving Patient Access to Compounded Medication Act of 2017. " HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-01-19T10:55:42.817000-05:00
2071145 FORGE FEDERAL AFFAIRS LLC 8ceea5fc-0372-43f1-be6b-4066e8425920 Q4 FORGE FEDERAL AFFAIRS LLC 400865535 LILLY USA LLC 2017 fourth_quarter PHA Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts. HOUSE OF REPRESENTATIVES 20000   0 0 2018-01-19T11:00:22.127000-05:00
2071442 BLUECROSS BLUESHIELD OF TENNESSEE 33d51643-eb27-47be-a3c8-f541a55ef119 Q4 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2017 fourth_quarter PHA General pharmacy and pharmaceutical issues; Opioid Abuse; prescription drug pricing; generic drug issues; HR2051; HR22312. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2018-01-19T11:21:27.633000-05:00
2071451 ALKERMES, INC. 2cccfc7e-1735-43b4-b33a-45ec0789ef3e Q4 ALKERMES, INC. 400458235 ALKERMES, INC. 2017 fourth_quarter PHA Public law #114-198, 21st Century Cures Opioid Implementation Awareness of outcomes data and the need for training on all medication assisted treatment Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Veterans Affairs, Dept of (VA)   1000000 0 0 2018-01-19T11:21:33.290000-05:00
2071956 COVINGTON & BURLING LLP a0c4f323-0628-4c97-ac33-24f6866b6b51 Q4 COVINGTON & BURLING LLP 11195 CELGENE CORPORATION 2017 fourth_quarter PHA Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-01-19T11:56:12.140000-05:00
2072082 BOCKORNY GROUP, INC. a4111502-f22a-4896-9fbb-f114d09466ed Q4 BOCKORNY GROUP, INC. 289773 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2017 fourth_quarter PHA Issues related to the pharmaceutical industry Issues related to the pharmaceutical drug supply chain Health & Human Services, Dept of (HHS),Natl Economic Council (NEC),White House Office 80000   0 0 2018-01-19T12:10:22.543000-05:00
2072084 CAREFIRST BLUECROSS BLUESHIELD 486e94db-4289-4a05-8108-7e3d89ab49e6 Q4 CAREFIRST BLUECROSS BLUESHIELD 401104608 CAREFIRST BLUECROSS BLUESHIELD 2017 fourth_quarter PHA Opioid Policy/Substance Use Disorders HOUSE OF REPRESENTATIVES,SENATE   140000 0 0 2018-01-19T12:10:23.857000-05:00
2072359 FOLEY & LARDNER LLP 83d36d57-cc7e-4bc4-9d8f-c74c46cfddf9 Q4 FOLEY & LARDNER LLP 15042 ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY 2017 fourth_quarter PHA FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-01-19T12:39:07.347000-05:00
2072364 KOUNTOUPES DENHAM CARR & REID, LLC 3f8f3a0c-77c2-4edf-9b4c-6c595e0cf135 Q4 KOUNTOUPES DENHAM CARR & REID, LLC 320918 BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) 2017 fourth_quarter PHA Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-01-19T12:39:09.833000-05:00
2072456 BOCKORNY GROUP, INC. 4b43ffcc-a731-48a2-a0cb-7a9803f25fbe Q4 BOCKORNY GROUP, INC. 289773 CVS HEALTH INC 2017 fourth_quarter PHA Issues related to PBM's Issues related to drug supply chain Issues related to drug pricing Issues related to Veterans health Issues related to opioid abuse Issues related to health reform proposals S.637 - Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 H.R.2212 - CREATES Act of 2017 Judiciary issues related to the drug supply chain Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 120000   0 0 2018-01-19T12:46:06.253000-05:00
2072495 UNIVERSITY OF IOWA 4026d870-2760-4269-a27f-2b3dc72b95e0 Q4 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2017 fourth_quarter PHA FY 17 and FY 18 appropriations for NIH Support for palliative care programs Support for 340B program Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Energy, Dept of,Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT)   86662 0 0 2018-01-19T12:48:23.720000-05:00
2072561 ASTRAZENECA PHARMACEUTICALS LP 91fd9fd6-598b-4634-aa7d-dbfb843ecf0c Q4 ASTRAZENECA PHARMACEUTICALS LP 54073 ASTRAZENECA PHARMACEUTICALS LP 2017 fourth_quarter PHA Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic Prior Authorization Under Medicare Part D (House) Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   620000 0 0 2018-01-19T12:53:54.907000-05:00
2072623 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM ee938e0c-38c8-4c57-a730-65ada8f7eea0 Q4 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2017 fourth_quarter PHA Graham-Cassidy-Heller HR 1628; S 2312; HR 4710 Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. Telehealth Improvements S 787 Any provision(s) expanding the use/payment/improvements for telehealth services. HOUSE OF REPRESENTATIVES,SENATE   29186 0 0 2018-01-19T13:02:28.937000-05:00
2072630 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION a90f75fe-3c8c-474c-acdc-39e047834c27 Q4 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2017 fourth_quarter PHA Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   228000 0 0 2018-01-19T13:03:30.217000-05:00
2072988 FOLEY & LARDNER LLP 930ecb7c-e842-4771-ad9d-7c49bf6b0575 Q4 FOLEY & LARDNER LLP 15042 BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) 2017 fourth_quarter PHA Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, with respect to market based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-01-19T13:34:45.100000-05:00
2073009 F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES 49a9700e-6c9f-4b93-a686-25d829cef9dc Q4 F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES 18411 F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES 2017 fourth_quarter PHA H.R. 3271 and S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017. Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   121189 0 0 2018-01-19T13:36:54.457000-05:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 1925.202ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API